Equashield, a Port Washington, New York-based provider of Closed System Transfer Devices (CSTDs) for the safe and simple handling of hazardous drugs, is building a new manufacturing plant.
The company will invest an estimated US$30m to build the new plant to meet the growing market demand for manual and automated hazardous drug compounding devices.
The new facility will be built on a three acre plot with an option to expand by another 1.5 acres.
The new plant will expand the manufacturing capabilities of Equashield's flagship CSTD, as well as the new Equashield Pro closed system drug compounding robot, first unveiled at the ASHP Midyear meeting.
"As Equashield continues to expand into new international markets, this plant will provide the capacity to significantly expand our product portfolio, while enabling us to fulfil worldwide need for current and future CSTD demand," said Marino Kriheli, co-founder of Equashield.
"With these enhanced capabilities Equashield can continue to make a difference for those who work with and around hazardous drugs."
Construction of the 112,000ft2 (10,405m2) building is expected to be completed in July 2019. It will include a 20,000ft2 (1,858m2) cleanroom space, incorporating the HVAC variable refrigerant flow (VRF) system for cooling and air conditioning. Production will be fully automated, from raw materials entry to packaging and palletising, to preserve sterility of products.
